Skip to main content
. 2022 Jun 23;56(5):794–801. doi: 10.1111/apt.17092

FIGURE 3.

FIGURE 3

Rate of clinical remission in the original RCTs and in the real‐world cohort stratified by disease and drug type. Remission rates were evaluated at 12 months for infliximab and adalimumab, and at 4 months for vedolizumab and ustekinumab, as done in the original RCTs.